NCT03834948 - AO-176 in Multiple Solid Tumor Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 4, 2019

Primary Completion Date

November 17, 2022

Study Completion Date

February 15, 2023

Conditions

Solid Tumor

Interventions

DRUG

AO-176

Humanized monoclonal antibody (mAb) targeting CD47

DRUG

AO-176 + Paclitaxel

Humanized monoclonal antibody (mAb) targeting CD47 and paclitaxel

DRUG

AO-176 + Pembrolizumab

Humanized monoclonal antibody (mAb) targeting CD47 and pembrolizumab

Trial Locations (10)

Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia

Virginia Cancer Specialists, Fairfax

University of Virginia, Charlottesville

Tennessee Oncology, Nashville

Oklahoma University, Stephenson Cancer Center, Oklahoma City

University of Southern California, Los Angeles

University of California San Francisco, San Francisco

Oregon Health Science University, Portland

Northwest Medical Specialties, Tacoma

Dana-Farber Cancer Institute, Boston